Oct 2 (Reuters) - Mesoblast Ltd MSB.AX :
* UPDATE ON BLA FOR GRAFT VERSUS HOST DISEASE-MSB.AX
* FDA RECOMMENDS CO CONDUCT AT LEAST 1 ADDITIONAL RANDOMIZED, CONTROLLED STUDY IN ADULTS AND/OR CHILDREN
* FDA ISSUED COMPLETE RESPONSE LETTER TO BIOLOGICS LICENSE APPLICATION FOR REMESTEMCEL-L
* FDA RECOMMENDS STUDY TO PROVIDE FURTHER EVIDENCE OF EFFECTIVENESS OF REMESTEMCEL-L FOR SR-AGVHD
* WILL URGENTLY REQUEST TYPE A MEETING WITH FDA TO DISCUSS POTENTIAL ACCELERATED APPROVAL WITH POST-APPROVAL CONDITION FOR ADDITIONAL STUDY
* FDA IDENTIFIED NEED FOR FURTHER SCIENTIFIC RATIONALE TO DEMONSTRATE RELATIONSHIP OF POTENCY MEASUREMENTS TO PRODUCT'S BIOLOGIC ACTIVITY